Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer

Autor: Toshiaki Wakayama, Masato Taki, Tomoko Funazo, Kazuhiko Nakagawa, Naoya Ikegami, Ryo Ariyasu, Chie Yoshimura, Chisato Konishi, Moon Hee Hwang, Satoshi Nakao, Yasuo Nishizaka, Kyohei Morita
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Oncology
Alectinib
Adult
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Carbazoles
non-small cell lung cancer (NSCLC)
Case Report
Antineoplastic Agents
Targeted therapy
03 medical and health sciences
0302 clinical medicine
Asian People
Piperidines
Internal medicine
hemic and lymphatic diseases
Carcinoma
Non-Small-Cell Lung

Internal Medicine
medicine
Anaplastic lymphoma kinase
Humans
alectinib
Anaplastic Lymphoma Kinase
Neoplasm Metastasis
Lung cancer
Protein Kinase Inhibitors
Chemotherapy
business.industry
Choroid Neoplasms
Cancer
Receptor Protein-Tyrosine Kinases
General Medicine
choroidal metastasis
medicine.disease
eye diseases
Radiation therapy
anaplastic lymphoma kinase (ALK)
030220 oncology & carcinogenesis
030221 ophthalmology & optometry
Female
sense organs
business
Zdroj: Internal Medicine
ISSN: 1349-7235
0918-2918
Popis: Choroidal metastasis is rare in cancer patients and it may cause visual disturbances that reduce their quality of life. In non-small cell lung cancer (NSCLC), targeted therapy against actionable driver mutations has gradually replaced radiotherapy as the treatment of choice for choroidal metastasis. Recently, there have been several case reports of choroidal metastasis in patients with anaplastic lymphoma kinase (ALK)-rearranged NSCLC. We herein report the case of a 40-year-old Japanese woman diagnosed with choroidal metastasis of an ALK-rearranged NSCLC who received alectinib as the first-line chemotherapy. Alectinib may be the best treatment for choroidal metastasis in patients harboring an ALK translocation because of its favorable side effect profile involving visual disturbances.
Databáze: OpenAIRE